Oncology

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Chief Medical Physicist at Texas Oncology combines breast cancer survivor insights with expertise in AI integration and personalized cancer treatment.

MRI segmentation models can now label 80 structures, but deployment is the hard part

Open-source MRI segmentation models can segment up to 80 structures. For imaging and oncology ops, deployment is the hard part.

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz’s journey as both a chief medical physicist and a breast cancer survivor offers a unique perspective into the dual experiences of being a cancer care provider and a patient. With over 23 years of experience at Texas Oncology, a leading oncology network in the United States, Dr. R

Rasonque’s 13.2-month survival result is about to hit hospital formularies

FDA cleared Revolution Medicines’ Rasonque for metastatic pancreatic adenocarcinoma. The ops work now is pathways, genotyping, and specialty pharmacy flow.

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech taps Sobi CEO Guido Oelkers as its next chief executive, with a mandate to turn a deep oncology pipeline into multiple approved products by 2030.

From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Inside Oncology Drug Development: Overcoming Resistance with Science

Scientists are racing to solve the cancer cell adaptation problem that renders even cutting-edge therapies ineffective over time

Growing the Future of Cancer Research: Inside the Promise of Organoids

Miniature lab-grown tissues are poised to revolutionize how researchers predict which cancer treatments will work for individual patients

Shaping the Future of Cancer Care Through Immuno-Oncology

Combination therapies and emerging cell-based treatments are reshaping how oncologists tackle cancer at the cellular level

Evolving Biomarkers: Charting the Future of Precision Medicine

The shift from broad treatments to targeted therapies hinges on identifying which patients will actually benefit from specific drugs

Pioneering Strategies to Unlocking the Potential of KRAS

Scientists are racing to overcome resistance mechanisms in newly approved KRAS therapies targeting the majority of difficult-to-treat cancers

Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation

Smaller pharma companies are accelerating drug development by leveraging advanced data analytics to streamline trials and regulatory pathways

Rising Cancer Diagnoses in Young Adults: Lifestyle Changes and Early Screenings can Lower Risks

Early interventions and lifestyle adjustments offer young adults a fighting chance against a disease that's striking earlier than ever before

Selecting and Finding the Best Healthcare Physicians Requires a Roadmap That Leads to Trust and Accessibility

Patients struggle to find trustworthy physicians in an oversaturated market where unnecessary procedures remain rampant